<DOC>
	<DOCNO>NCT00752323</DOCNO>
	<brief_summary>RATIONALE : Imaging procedure use aminolevulinic acid may help find diagnose residual tumor patient grade IV malignant astrocytoma undergo surgery remove tumor . PURPOSE : Our primary long-term goal improve completeness surgical resection malignant brain tumor image- guide fluorescence localization . We hypothesize use qualitative fluorescence image point PpIX concentration quantification enable complete tumor resection normal direct ( i.e. , white light ) visualization , thereby improve patient survival .</brief_summary>
	<brief_title>Imaging Procedure Using ALA Finding Residual Tumor Grade IV Malignant Astrocytoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess 2 dos 5-ALA , 10kg/mg 20kg/mg , determine optimum ALA dose term sensitivity specificity residual tumor . We compare residual tumor detection vivo qualitative quantitative fluorescence image use histology biopsied tissue gold standard . Secondary - Assess correlation record vivo qualitative assessment fluorescence signal neurosurgeon post-surgical ( i.e. , ex vivo ) absolute PpIX concentration detect intraoperatively ex vivo tissue biopsy . Tertiary - To determine association presence fluorescence surgical cavity post-operative image enhancement MRI . This include relationship amount location residual tumor detect fluorescence , PpIX concentration , intra-operative frameless stereotaxy follow maximal resection versus amount location tumor image post-operatively via CT and/or MRI . OUTLINE : This study enroll evaluable patient undergo surgical resection malignant , grade IV gliomas two group : , newly diagnose GBM recurrent GBM . Patient , group ( primary v recurrent GBM ) randomize one 2 level ALA dose ( 10 and20 mg/kg ) give orally 6 hour prior anticipate midpoint surgery . Patients consent protocol randomly assign one two ALA dose group . Randomization stratify whether tumor newly diagnose ( i.e . de novo ) recurrent . The data center prepare seal , opaque envelope randomize assignment ALA dose administration time notify pharmacy trial site correct ALA dose prepare . - Arm I : Newly diagnose GBM patient receive oral aminolevulinic acid ( 10mg/kg ) 6 hour midpoint surgery . - Arm II : Newly diagnose GBM patient receive oral aminolevulinic acid ( 20mg/kg ) 6 hour midpoint surgery . - Arm III : Recurrent GBM patient receive oral aminolevulinic acid ( 10mg/kg ) 6 hour midpoint surgery . - Arm IV : Recurrent GBM patient receive oral aminolevulinic acid ( 20mg/kg ) 6 hour midpoint surgery . For patient new recurrent disease , biopsy take six site identify surgeon : tumor center , tumor edge , area surround tumor ( safe ) , area see fluoresce intraoperatively area MR enhancement outside tumor region ( accomplish safely ) . Prior collect biopsy reading take biopsied location PpIX point probe surgeon . For 6 biopsy , divide 3 part distribute analysis follow : one portion send pathologist assessment tumor percentage , one portion evaluate Division Biophysics University Toronto PpIX concentration assessment fluorescence .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>Tumor Pathology : Newly diagnose recurrent malignant glioma WHO grade IV Location : Supratentorial Resection : Tumor must judge suitable resection basis image study . Consent : Patients must able give write , informed consent approve local IRB Newly Diagnosed Tumors : Patients newly diagnose Grade IV glioma previously treat cranial radiation therapy Recurrent Tumors : Patients recurrent Grade IV glioma fail cranial radiation therapy Pregnant woman breast feeding Individuals history cutaneous photosensitivity , porphyria , hypersensitivity porphyrin , photodermatosis , exfoliative dermatitis Individuals history liver disease last 12 month Individuals AST , ALT , ALP , bilirubin &gt; 2.5x normal upper limit time previous 2 month Individuals plasma creatinine &gt; 180 Î¼mol/L Individuals unable comply photosensitivity precaution Individuals without grade IV glioma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
</DOC>